A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer (NCT00679211)
Study of ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) administered to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
This trial is sponsored by Genentech, Inc. 
- Condition: Metastatic Breast Cancer
- Phase: II
- Enrollment: 110
- Start: August 2008
- Completion: April 2011
- Last verified: May 2013
Last Editorial review: July 28, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.